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Abstract
Background: Different strategies of ritonavir-boosted lopinavir monotherapy have been
explored; however, data regarding salvage therapy among HIV-infected patients who failed
nucleoside reverse transcriptase inhibitor (NRTI) and non-nucleoside reverse transcriptase
inhibitor (NNRTI) is still limited.
Methods: A prospective study was conducted among HIV-infected patients who failed NNRTI-
based antiretroviral therapy with M184V, TAMs, and NNRTI mutations, and were naïve to
protease inhibitor. LPV/r at 400/100 mg and lamivudine 150 mg were given twice daily. CD4 and
HIV-1 RNA were monitored at week 0, 12, 24, and 48. LPV Cmin was assayed for the first
14 patients using HPLC.
Results: There were 40 patients with a mean age of 37 years and 70% were male. Median (IQR)
baseline CD4 was 123 (37-245) cells/mm3 and median (IQR) HIV-1 RNA was 55,800 (9,670-
100,000) copies/mL. By intend-to-treat analysis, 30 (75%) and 24 (60%) patients achieved HIV-1
RNA at <400 and <50 copies/mL, respectively. In as-treated analysis, the corresponding rates were
29 (83%) and 23 (67%), respectively. Low-level viral rebound was found in 6 (15%) patients at week
48. Medians CD4 at week 12, 24, 36 and 48 were 249, 283, 307, and 351 cells/mm3 and significantly
changed from baseline (all, P < 0.05). At 6 and 12 weeks, median (min-max) LPV Cmin was 6.52
(1.62-11.64) mg/L and 5.79 (0.75-16.31) mg/L, respectively. There were increments of mean total
cholesterol and triglyceride at 48 weeks from baseline (P < 0.05).
Conclusion: LPV/r monotherapy with recycled lamivudine can maintain virological suppression in
a substantial proportion of patients failing NNRTI-based regimen and provides adequate plasma
concentrations of LPV although the incidence of low-level viremia is relatively high.
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Currently, non-nucleoside reverse transcriptase inhibitor
(NNRTI)-based highly active antiretroviral therapy
(HAART) is widely prescribed as an initial therapy for
treatment naïve HIV-infected patients, particularly in
many resource-constrained countries [1]. However, in
patients who have delayed detection of treatment failure
in this setting, the virus is often resistant to most existing
nucleoside reverse transcriptase inhibitors (NRTIs) and
NNRTIs even failing from the first regimen [2]. As a
consequence, constructing the potent salvage regimens
that combined 2 or 3 fully active drugs from existing drug
classes is often impossible in many resource-constrained
countries where new agents, such as integrase inhibitor
and chemokine receptor antagonist, are neither available
nor affordable. Nevertheless, the goal of attaining
undetectable plasma HIV-1 RNA is remain mandatory
[3]. To date, several clinical studies derived from the
western countries that included 2 or more active drugs
clearly demonstrate effective therapeutic strategies for
antiretroviral (ARV)-experienced HIV-1 infected patients
[4,5]. Hence, using ritonavir-boosted protease inhibitor
in a salvage therapy was considered to be an option in the
resource-constrained countries and the limitations of
remaining active NRTIs usually lead to ritonavir-boosted
protease inhibitor monotherapy as a salvage regimen.
Among several previous reports using ritonavir-boosted
protease inhibitor, ritonavir-boosted lopinavir mono-
therapy has been extensively studied so far [6]. Different
strategies of ritonavir-boosted lopinavir monotherapy
have been explored; however, most related clinical trials
studied this regimen as either a treatment simplification
strategy or induction therapy in treatment-naïve patients
[6]. A strategy to use ritonavir-boosted lopinavir mono-
therapy as a salvage regimen is not available. On the
other hand, previous studies showed that continuation
of lamivudine after emerging of the M184V mutation
had somewhat benefit on immunological response and
clinical progression in patients who had limited options
of salvage regimens [7]. Moreover, there is neither
additional any other mutation nor increase resistance
to other antiretroviral drugs. Thus, this is the reason why
we added lamivudine to decrease viral fitness in the
study regimen. The objective of this study was to assess
48-week treatment responses, tolerability, and steady-
state minimum plasma concentrations of ritonavir-
boosted lopinavir monotherapy for salvage therapy in
HIV-1 infected patients who failed antiretroviral regi-
mens containing NRTI and NNRTI.
Materials and methods
All patients followed at Bamrasnaradura Infectious
Diseases Institute, Ministry of Public Health, Thailand,
between April 2007 and February 2008 were evaluated
for antiretroviral therapy failure based on guidelines for
antiretroviral therapy of the Thai AIDS Society, which
define failure as viral load >1,000 copies/mL after 6
months of receiving treatment or a rebound of viral load
to >1,000 copies/mL in any duration after undetectable
viral load [8]. Inclusion criteria were as follows: (1) HIV-1
infected patients >18 years of age, (2) failed NNRTI-based
antiretroviral therapy with M184V, thymidine analogue
mutations (TAMs) and NNRTI-associated mutations and
(3) had plasma HIV-1 RNA >1,000 copies/mL. The
patients were excluded if they had a history of exposure
to protease inhibitor or receipt a medication that has
drug-drug interactions with lopinavir. All patients were
followed until 48 weeks of treatment. Ritonavir-boosted
lopinavir in soft gel formulation at 400/100 mg and
lamivudine at 150 mg were given twice daily. Clinical
characteristics and findings from physical examinations
were recorded for each patient. Patients were assessed as
well as CD4 cell counts (flow cytometry) and plasma
HIV-1 RNA (Roche Amplicor, version 1.5) at follow-up
visits at weeks 0, 12, 24, and 48. The lower limit of
detection for the HIV-1 RNA level is 50 copies/mL.
Virological failure was defined as either a plasma HIV-1
RNA level >1,000 copies/mL after having a previously
undetectable value. Serum was obtained at 24 hours after
dosing to assay lopinavir concentration for the first 14
patients at the HIV Netherlands-Australia-Thailand Clin-
ical Research Laboratory, which is located at the
Chulalongkorn Medical Research Center (Bangkok), by
high-performance liquid chromatography. This assay was
performed in accordance with the protocol developed by
the Department of Clinical Pharmacology at the Uni-
versity Medical Centre Nijmegen (Nijmegen, the Nether-
lands) [9].
All analyses were performed using SPSS, version 14.0.
Mean values (± standard deviations) or median values
(with interquartile ranges; IQRs) and frequency were
used to describe the patients’ characteristics for contin-
uous and categorical data, respectively. The proportion
of patients with plasma HIV-1 RNA <50 copies/mL after
48 weeks of ART were analyzed as intend-to-treat and as-
treated. Paired t-test was used to compare parameters
between time points. P values < 0.05 were considered to
be statistically significant. The institutional ethics com-
mittees of Bamrasnaradura Infectious Diseases Institute
and Ministry of Public Health approved the study. All
patients signed the inform consent.
Results
Table 1 summarizes subject characteristics and labora-
tory parameters. There were 40 patients with 70% male
and a mean age of 37 years. The frequencies of
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thymidine analogue associated mutations (TAMs) were
17 (43%) D67N, 16 (40%) T215FY, 8 (20%) M41L,
6 (15%) K60R, 6 (15%) L210W, 2 (5%) K219Q. Q151M
and L74V were found in 7 (18%) and 2 (5%),
respectively. The prevalence of patients with ≥1 major
mutation conferring drug resistance to NNRTIs was
100%.
The proportion of patients who had different stratum of
plasma HIV-1 RNA at weeks 48 of treatment by intend-
to-treat analysis was displayed in figure 1. By intend-to-
treat analysis, 33 (83%), 30 (75%) and 24 (60%)
patients achieved plasma HIV-1 RNA at <1000, <400 and
<50 copies/mL after 48 weeks, respectively. In as-treated
analysis (excluded dropped out, study drug discontinua-
tion by any reason and transferred), the corresponding
rates were 33 (94%), 29 (83%) and 23 (67%),
respectively. Low-level viral rebound, defined as having
plasma HIV-1 RNA between 50 and 400 copies/mL after
having <50 copies/mL during the follow-up period, was
found in 6 (15%) patients at week 48. Nine of 11
patients with plasma HIV-1 RNA >50 copies/mL had
value between 50 and 1,000 copies/mL. In 11 patients,
all but two had never achieved plasma HIV-1 RNA <50
copies during the study period. Two remaining patients
developed virological rebound at week 48. No major
PRAM was found in 2 patients who had virological
rebound above 1000 copies/mL. Means CD4 cell counts
changes at weeks 12, 24, 36 and 48 were shown in
Figure 2. These measures significantly changed from
baseline (all P values < 0.05). At 6 and 12 weeks of
treatment, median (min-max) lopinavir minimum con-
centrations were 6.52 (1.62-11.64) mg/L and 5.79 (0.75-
16.31) mg/L, respectively. All but one patient achieved
lopinavir minimum concentrations greater than the
recommended minimum concentration that was 1 mg/
L. With regard to adverse reactions, 1 patient discon-
tinued ritonavir-boosted lopinavir due to diarrhea after
the first 2 weeks of ritonavir-boosted lopinavir treat-
ment. Compared measures at week 48 to baseline values,
there were increments ofmean total cholesterol (206mg/dL
vs. 170 mg/dL, P < 0.05) and mean triglyceride (348 mg/dL
vs. 216mg/dL; P < 0.05). Eight patients and 24 patients had
total cholesterol to HDL ratio ≥6.5 and ≥4 at week 48,
respectively. Three patients needed to initiate anti-lipid
Table 1: Baseline characteristics of 40 HIV-infected patients
Baseline characteristics Number (%), n = 40
Demographics
Age, mean ± SD, years 37.1 ± 8.0
Male gender, number (%) 28 (70)
Body weight, mean ± SD, Kilograms 57 ± 21
Body mass index, mean ± SD 22.7 ± 4.6




CD4 cell counts at virological failure, mean ±
SD, cells/mm3
144 ± 124
Percentage of CD4 cell at virological failure,
mean ± SD, %
7.7 ± 5.1




Log, copies/mL 4.8 (4.0-5.0)
Total cholesterol, mean ± SD, mg/dL 165 ± 42
HDL choleterol, mean ± SD, mg/dL 41 ± 30
Triglyceride, mean ± SD, mg/dL 172 ± 117
Total cholesterol:HDL ratio ≥6.5, number (%) 2 (5)
Fasting blood sugar, mean ± SD, mg% 100 ± 27
Patients with ≥3 TAMs, number (%) 13 (32.5%)
Patients with Q151M, number (%) 7 (18%)
Figure 1
Percentage of patients who had different stratum of
plasma HIV-1 RNA at weeks 48 of treatment by
intend-to-treat analysis.
Figure 2
Means and its standard deviations of CD4 cell counts
changes at weeks 12, 24, 36 and 48 of treatment.
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agents during the follow-up period. There was an increment
of fasting blood sugar from week 48 to baseline value
(110 mg% vs. 100 mg%, P = 0.210). Two patients were
receiving oral hypoglycemic agents at enrollment and
another two patients had started oral hypoglycemic agents
during the follow-up period.
Discussion
As NNRTI-based HAART regimen is extensively pre-
scribed in many resource-limited countries and due to
delayed detection of virological failure from lacking the
effective monitoring tools and/or inadequate infrastruc-
ture in the real-life practice, extensive NRTI and NNRTI-
associated mutations could be problematic in those area.
To the best of our knowledge, this is the first clinical trial
that has shown clinical outcome and pharmacokinetic
measures of ritonavir-boosted lopinavir together for the
patients experienced with NRTIs and NNRTIs although it
was conducted in a small study. Our data indicate that
ritonavir-boosted lopinavir monotherapy combined
with recycled lamivudine can maintain virological
suppression in a substantial proportion of patients
who were failing NNRTI-based regimens with M184V,
TAMs and NNRTI mutations but were naïve to protease
inhibitor. Using intend-to-treat analysis, 60% of patients
reached the virological success, i.e., plasma HIV-1 RNA
<50 copies/mL, after 48 weeks of treatment. This result is
relatively consistent with a recent report that involved
antiretroviral-naïve patients by Delfraissy and colleagues
[10]. Of 84 patients in ritonavir-boosted lopinavir
monotherapy arm, 67% and 79% had achieved unde-
tectable plasma HIV-1 RNA by intend-to-treat and as-
treated analysis, respectively. In addition, Gathe and
colleagues also reported 77% of antiretroviral naïve
patients who were received treatment with ritonavir-
boosted lopinavir had undetectable plasma HIV-1 RNA
[11]. Regarding immunological response, a higher CD4
cell count while receiving antiretroviral treatment
gained, a lower risk for AIDS-related events was
associated [12,13]. The present study reveals that
ritonavir-boosted lopinavir showed a great performance
on the immunological response after 48 weeks of
treatment. A previous study showed that a regimen of
ritonavir-boosted lopinavir plus 2 NNRTIs had a greater
CD4 cell count response when compared with efavirenz
plus 2 NRTIs [14].
Interestingly, 15% of our patients had low level viremia.
This number is considered to be a significant proportion.
Of this proportion, 5% achieved undetectable plasma
HIV-1 RNA and 10% still had low level viremia at 72
weeks (data not shown). One possible explanation is the
lack of viral suppression in some compartments, such as
genital secretion and cerebrospinal fluid [15]. Another
previous proposed explanation is an alternative pathway
of protease inhibitor resistance facilitated by the absence
of the NRTI drugs, different HIV subtypes influence on
polymorphisms, and a non-adherence issue [16,17].
There was an increasing risk for virological failure in
patients with suboptimal adherence. The current guide-
lines from Department of Health and Human Services
(DHHS) suggested minimum target for lopinavir at
>1 mg/L [5]. Therefore, almost all of our patients had
their minimum concentration levels exceed the target
cut-off value. However, a single therapeutic drug
monitoring cannot exclude non-adherence, long-term
follow-up is therefore warranted.
Regarding adverse reactions, the most commonly
reported side effect associated with lopinavir/ritonavir
is mild to moderate diarrhea [18,19]. In addition, nausea
and vomiting, changes in blood lipid levels, elevated
transaminase levels and altered blood glucose profiles
also have been widely reported [19]. One of our patients
needed to discontinue ritonavir-boosted lopinavir due to
gastro-intestinal adverse event. Lopinavir/ritonavir soft
gel capsules had been used in the present study instead
of new lopinavir/ritonavir tablet because tablet formula-
tion had not been available in the country during the
study period. The lopinavir/ritonavir tablet formulation
could lower the rate of adverse gastro-intestinal symp-
toms associated with the soft-gel capsules. Although this
study was not designed to directly assess metabolic
complication, it could revealed a great impact of
ritonavir-boosted lopinavir on serum lipid parameters,
included total cholesterol, LDL-cholesterol, triglyceride
and total cholesterol to HDL-cholesterol ratio, at 48
weeks of treatment. Likewise, a proportion of patients
had total cholesterol to HDL-cholesterol ratio above cut-
off value; i.e. ≥4, that related to high risk of coronary
heart disease [20,21].
In treatment-experienced patients failing NNRTI-based
regimens with limited NRTI options, switching to at least
2 fully active drugs to an optimized antiretroviral
regimen is principally the best strategy so far. In patients
with earlier first-line treatment failure and have devel-
oped either only M184V or with few TAMs, the option of
NRTI backbone is still not limited. In these cases, there is
a possibility to include 1 or 2 active NRTI drugs in
combination with a new drug class, such as PIs, to assure
the effectiveness of the regimen. Thus in settings where
other new ARV classes beside PIs cannot be assessable,
early detect virological failure is crucial to preserve the
NRTI backbone. While waiting for a randomized control
trial to prove HIV monotherapy with ritonavir-boosted
protease inhibitor in these particular patients, the
present data provide support to physicians currently
facing choices of salvage regimen options in many
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resource-constrained countries. Ritonavir-boosted lopi-
navir combined with recycled lamivudine to decrease
viral fitness can maintain virological suppression in a
substantial proportion of patients failing NRTI and
NNRTI with M184V and provides adequate plasma
concentrations of lopinavir although incidence of low-
level viremia is relatively high. A further larger study
would be required to assess the risk and benefit of this
proposed strategic treatment in the resource-constrained
settings.
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